Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development
Authors:
Open Access
- 4 March 2008
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 98 (5) , 900-906
Abstract
A population pharmacokinetic model based on data from three phase I studies was to be developed including a covariate analysis to describe the concentration–time profiles of matuzumab, a novel humanised monoclonal antibody. Matuzumab was administered as multiple 1 h i.v. infusions with 11 different dosing regimens ranging from 400 to 2000 mg, q1w–q3w. For analysis, 90 patients with 1256 serum concentration–time data were simultaneously fitted using the software NONMEM™. Data were best described using a two-compartment model with the parameters central (V1) and peripheral distribution volume (V2), intercompartmental (Q) and linear (CLL) clearance and an additional nonlinear elimination pathway (Km, Vmax). Structural parameters were in agreement with immunoglobulin characteristics. In total, interindividual variability on Vmax, CLL, V1 and V2 and interoccasion variability on CLL was 22–62% CV. A covariate analysis identified weight having an influence on V1 (+0.44% per kg) and CLL (+0.87% per kg). All parameters were estimated with good precision (RSE<39%). A robust population pharmacokinetic model for matuzumab was developed, including a nonlinear pharmacokinetic process. In addition, relevant and plausible covariates were identified and incorporated into the model. When correlated to efficacy, this model could serve as a tool to guide dose selection for this ‘targeted’ cancer therapy.Keywords
This publication has 35 references indexed in Scilit:
- Pharmacokinetics of Monoclonal Antibodies2006
- Overview of monoclonal antibodies in cancer therapy: present and promiseCritical Reviews in Oncology/Hematology, 2005
- Epidermal growth factor receptor inhibition strategies in oncologyEndocrine-Related Cancer, 2004
- Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- The epidermal growth factor receptor–tyrosine kinase: A promising therapeutic target in solid tumorsSeminars in Oncology, 2003
- EGF receptorThe International Journal of Biochemistry & Cell Biology, 1999
- Increasing the serum persistence of an IgG fragment by random mutagenesisNature Biotechnology, 1997
- The importance of modeling interoccasion variability in population pharmacokinetic analysesJournal of Pharmacokinetics and Biopharmaceutics, 1993
- Building population pharmacokineticpharmacodynamic models. I. Models for covariate effectsJournal of Pharmacokinetics and Biopharmaceutics, 1992
- Metabolic properties of IgG subclasses in manJournal of Clinical Investigation, 1970